Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Ibrutinib Associated With Superior QoL in MCL Compared With Temsirolimus

July 12th 2017

Phase III results from the RAY trial showed that patients with mantle cell lymphoma treated with ibrutinib (Imbruvica) had superior quality of life compared with patients treated with temsirolimus.

TP53 Mutations Have Independent Prognostic Value in MCL

July 11th 2017

Christian Winther Eskelund, MD, discusses TP53 mutations in mantle cell lymphoma.

Dr. Tam on the Toxicities of Ibrutinib Plus Venetoclax in MCL

July 5th 2017

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the toxicities of the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

Dr. Eskelund Discusses TP53 Mutated Mantle Cell Lymphoma

June 28th 2017

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses TP53-mutated mantle cell lymphoma (MCL).

Dr. Eskelund on Study of TP53 Mutations in Mantle Cell Lymphoma

June 24th 2017

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses a study of TP53 mutations in mantle cell lymphoma.

Combination of Ibrutinib and Buparlisib Shows Promise in MCL and other NHLs

June 16th 2017

Connie Batlevi, MD, PhD, discusses the combination of ibrutinib and buparlisib in MCL.

Ibrutinib-Resistant Patients a Core Challenge in MCL

June 16th 2017

Bijal D. Shah, MD, discusses the current treatment paradigm of MCL, what therapies are moving through the pipeline at a rapid rate, the potential benefit with CAR T-cell therapy, and pivotal biomarker studies currently being conducted.

5-Year Follow-Up Confirms Efficacy of Frontline Bendamustine Plus Rituximab in MCL, iNHL

June 15th 2017

Ian W. Flinn, MD, PhD, discusses the 5-year update of the BRIGHT study in MCL and NHL.

Expert Discusses Ibrutinib/Venetoclax Combo in MCL

June 15th 2017

Constantine S. Tam, MD, discusses phase III PCYC-1143 trial is investigating the combination of ibrutinib and venetoclax as well as the next steps with venetoclax /ibrutinib and other rational combinations in MCL.

Dr. Batlevi on Safety With Ibrutinib/Buparlisib in MCL, FL, and DLBCL

June 14th 2017

Connie Batlevi, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses safety results of a phase I study evaluating the combination of ibrutinib (Imbruvica) and buparlisib in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Dr. Tam on the Combination of Ibrutinib Plus Venetoclax in Mantle Cell Lymphoma

June 14th 2017

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

Dr. Hamlin on Early Study of Ibrutinib/Buparlisib in MCL, FL, and DLBCL

June 12th 2017

Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Expert Explains Evolution of MCL Treatment

May 30th 2017

Peter Martin, MD, discusses the evolution of treatment and ongoing research for patients with mantle cell lymphoma.

Dr. Martin on the Role of Transplant in Mantle Cell Lymphoma

May 23rd 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the role of transplant in the field of mantle cell lymphoma (MCL).

Dr. Ansell on Promising Combinations Being Studied in MCL

May 17th 2017

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses promising combinations in the pipeline for mantle cell lymphoma (MCL).

Dr. Nowakowski on Next Steps With Emerging Agents in MCL

May 16th 2017

Grzegorz S. Nowakowski, MD, an assistant professor of Medicine at Mayo Clinic, discusses the status of emerging agents moving through the pipeline of mantle cell lymphoma.

Dr. Leonard on Rituximab Maintenance Strategy for Patients With MCL

May 15th 2017

John P. Leonard, MD, professor of medicine at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the maintenance strategy of rituximab (Rituxan) for patients with mantle cell lymphoma (MCL).

Expert Looks to Genetic Testing for Next Leap in MCL

May 8th 2017

Grzegorz S. Nowakowski, MD, discusses ongoing efforts to determine prognostic factors of mantle cell lymphoma and what other challenges lie ahead.

Dr. Martin on Patient Preferences With MCL Treatment

May 5th 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian, discusses preferences patients have for their treatment of mantle cell lymphoma (MCL).

Dr. Ansell on Recent Therapeutic Advancements in MCL

May 2nd 2017

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses some of the recent therapeutic advancements that have been reported in the field of mantle cell lymphoma (MCL).